2M.D. Associate Professor, Ankara Training and Research Hospital, Eye Clinic, Ankara/TURKEY Purpose: To evaluate the 2 year visual and anatomical outcome of cases that received intravitreal ranibizumab therapy for wet age-related macular degeneration (AMD).
Materials and Methods: The medical records of patients who received intravitreal ranibizumab therapy for wet AMD was examined retrospectively. The visual acuity (VA), biomicrospic anterior chamber examination, dilated fundus examination and optical coherens tomography (OCT) findings were evaluated. After the 3 loading dose ranibizuamab injections were repeated according to the VA, fundoscopic examination and OCT findings.
Results: A mean of 5.8 injections were performed to 31 eyes of 30 patients included to the study. After the loading doses there was a gain of 12 letters in VA. At the end of 12 month, an increase of 5.3 letters compared to the baseline was determined. At the end of the 2nd year the visual aquity was at the same level compared to the baseline. The decrease in central foveal thickness compared to the baseline at 3rd, 12th and 24th months was 84, 81 and 52.1 μm respectively.
Conclusion: İntravitreal anti-VEGF therapy is an effective method for AMD treatment. Injections performed in case when needed are effective in protecting visual acuity. With treatment anatomically effective results can be obtained.
Keywords : Age-related macular degeneration, ranibizumab